NCT06606821View on ClinicalTrials.gov

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 20, 2027

Study Completion Date

August 1, 2028

Conditions
Coronary Artery DiseaseCoronary Microvascular DysfunctionOverweight or ObesityStable Angina PectorisChronic Coronary Artery DiseaseAtherosclerosis Cardiovascular Disease
Interventions
DRUG

Tirzepatide

Investigational drug will be administered as a sc. injection once-weekly.

DRUG

Placebo

Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.

Trial Locations (3)

2100

NOT_YET_RECRUITING

Rigshospitalet, Copenhagen

2730

RECRUITING

Steno Diabetes Center Copenhagen, Herlev

2900

RECRUITING

Gentofte Hospital, Gentofte Municipality

All Listed Sponsors
lead

Tina Vilsbøll

OTHER